

About TTBD

For Inventors

Available Technologies

Startups

NEWS

There are several new and exciting developments in the office of Technology Transfer & Business Development. TTBD's efforts have recently culminated in the finalization of a multiyear drug target discovery program agreement with a top pharmaceutical company. This deal is a unique partnership between OHSU and this company and the first of its kind with an academic university in the United States for this pharmaceutical partner. This deal will not only bolster an emerging target discovery program at OHSU but also presents the opportunity for additional relationships to form with this partner. More news on this new program is sure to follow. Last month members of TTBD participated in the TechConnect World Innovation Conference & Expo along with the State of Oregon, signature research centers, fellow universities and companies all from Oregon. TTBD not only was able to talk about the research and innovation happening at OHSU in an attempt to find new licensing and business partnerships, but also was able to promote the advantages of doing business in the State of Oregon.

On November 5th, TTBD will be launching the OHSU MedTech Alliance, a platform for investors and industry representatives to stay up-to-date on early stage medical device technologies developed at OHSU. This event along with the Startup Symposium (see below) will help open more doors for OHSU entrepreneurs, faculty, researchers and students to meet and interact with investors and industry professionals, and through these interactions help move technologies to the marketplace. OHSU innovators interested in participating in the MedTech Alliance and/or starting a company need to work with TTBD to discuss their technologies and the commercialization process.

EVENTS



Tuesday, July 22, 2014

Oregon Bioscience Association
"BioForum: Changes in Patent Law Affecting the Bioscience Industry"

5:30 - 8:00 pm

Moss Adams LLP, 805 SW Broadway,
Portland, OR 97205

Thursday, August 7, 2014

TTBD Lunch & Learn Presentation
"How to Pitch to Industry"

12:00 - 1:00 pm

Mackenzie Hall 2201, Marquam Hill Campus

September 15-17, 2014

Oregon Bioscience Association
"2014 Oregon Bio Annual Conference: An Industry Inflection Point"

Marylhurst University, 07600 Pacific Hwy, Marylhurst, OR
97036

Tuesday, September 23, 2014

OHSU MedTech Alliance
"MedTech Alliance Pre-launch Panel Event"

5:00 - 7:30 pm

Ater Wynne, 1331 NW Lovejoy St #900, Portland, OR 97209

INTERNSHIP PROGRAM

TTBD is seeking three new part-time volunteer interns for the 2014 – 2015 academic year. Interns provide a valuable service by assisting with technology development and the transition of technology from laboratory to market for the benefit of the public. In return, interns gain valuable knowledge and skills that can be applied in a wide range of professions. Past TTBD interns have gone on to pursue careers in technology transfer, patent law, and startup development.

The application deadline for a part-time academic year-long unpaid internship is August 15, 2014. Qualified applicants must hold a bachelor's degree in a life science, a physical science, and/or engineering and be pursuing or have received a graduate-level degree in science, medicine, engineering, business, or law. Additionally, qualified candidates must have an interest in intellectual property, technology transfer, and/or business development as a career goal. To learn more about the TTBD internship program and how to apply, please visit the [Careers and Internships](#) page on our website.

NEW STAFF MEMBERS AND PROMOTIONS

Nicole D.W. Garrison

Nicole Garrison has recently been promoted into the role of Database and Compliance Administrator in TTBD. In this new role, Nicole will be managing the unique database systems within TTBD and also assisting the multiples teams within the office with various compliance responsibilities. In relation to agreements established by TTBD this includes compliance by OHSU and its employees as well as OHSU's external partners. Nicole was formerly the department's Executive Assistant.

Alexandra Sanderson

Sasha joined TTBD in early July as the new Administrative Specialist. Sasha will be assisting TTBD in a number of areas, but she will also be assisting the other departments located in the Bancroft building. Sasha comes to TTBD after serving for 3 years as a Student Worker in the Facilities & Logistics department at OHSU.

SAVE THE DATE: 2014 TTBD AWARDS

The 2014 Technology Transfer & Business Development Awards will be presented on the evening of October 6th in the new Collaborative Life Science Building (CLSB) in the PSU Lecture Hall. This event is open to any OHSU employee or student to attend.

The TTBD Awards event is a wonderful opportunity for all of OHSU to honor those who are making significant contributions to new technology, business partnerships, technology commercialization, and new business formation. Distinguished awards will be given this year in the areas of New Inventor of the Year, Technology Transfer Achievement Award, Business Partnership Award, and the TTBD Appreciation Award. Come support your friends and colleagues at this very special event. Further details of the event to follow.



SAVE THE DATE: TTBD STARTUP SYMPOSIUM

TTBD will host the 3rd annual OHSU Startup Symposium on November 6th, 2014 in the Vey Conference Center. This conference is primarily for OHSU's faculty and startup companies to help connect them with the investment community. It is an opportunity to learn from one another and also from experts on "what it takes to start a company."



This year, TTBD will be inviting a number of participants from corporate venture groups; both local and out of town venture capital groups and business development representatives from pharmaceutical companies. Select OHSU attendees will have an opportunity to participate in 1:1 pre-screened meetings with these investors and corporate business development representatives. To learn more about the Startup Symposium, feel free to contact [Daphne Emerson](#), TTBD Startup Associate, with any questions or concerns.

ALLEGORY VENTURE FUND

In an effort to accelerate venture investment in life science companies in Oregon, OHSU is collaborating with the Portland based Allegory Venture Partners GP, LLC in a bioscience funding and commercialization effort.

OHSU will give Allegory Venture Partners up to \$1.2M over an expected period of two years on a milestone basis to support the launch and operation of the fund. The Allegory Venture Partners will attempt to raise a minimum of \$40M within that period. Targeting a total raise of \$80M, "Fund I" is expected to provide seed and follow on funding to emerging life science companies. OHSU will disclose certain startup opportunities to Allegory Venture Partners on a non-exclusive basis and the fund will be free to invest both locally and nationally.

The Allegory Venture Partners expect to make venture capital investments in emerging stage life science companies in:

- a) Healthcare IT, software and applications
- b) Healthcare services
- c) Medical devices and diagnostics
- d) Research tools and technologies

To read more on OHSU's partnership with Allegory Venture Partners, see the story featured in the [Portland Business Journal](#).

TTBD EDUCATION: PATENT SECTION 101

Recently, the US Patent and Trademark Office (USPTO) issued new guidelines on the eligibility for patent of claims reciting "laws of nature/natural principles natural phenomena, and/or natural products" implementing the Supreme Court's recent decisions in [Myriad and Mayo](#). In the four months since the guidelines were announced, many inventions previously considered patentable are now being rejected. Many commentators (exemplified by this recent article in [Science](#)), believe that if left to stand; the new guidelines will have "chilling" effects on efforts to commercialize new biotechnology inventions.

The two Supreme Court decisions and the guidelines have impacts on two types of inventions commonly developed at OHSU. The first type involves biomolecules - naturally occurring nucleic acid or protein molecules (including any fragment or domain of a nucleic acid or protein) or any naturally occurring chemical compounds. All such compounds are now considered unpatentable even if they are recombinantly or chemically synthesized. Current indications suggest that cDNAs as well as monoclonal antibodies and nucleic acids encoding them are still patentable.

The second type involves molecular diagnostic tests - generally, a test that correlates the expression of a set of mRNA and/or protein molecules with a disease state. The reasoning is that the correlation is merely a naturally occurring cause and effect relationship and that without something more to differentiate it, such a test is unpatentable. Put another way, if the correlation between the marker and the disease state is the only thing new about the invention, then the test is not a patentable invention.

As this is a very complex topic, please feel free to contact [Jeff Jackson](#), Senior Patent Associate at OHSU with specific questions at 4-9906.

Technology Transfer & Business Development

Phone: 503-494-8200 | Fax: 503-494-4729 | techmgmt@ohsu.edu | www.ohsu.edu/techtransfer

Bancroft Building | Mail Code: L106TT
0690 SW Bancroft Street Portland, OR 97239

